The sales of prescription drugs (Rx) reached a value of RON1.85 billion, down 16.2% on the year, while sales of over-the-counter drugs (OTC) stood at RON0.54 billion, up 11.6% on the year. Sales to hospitals reached RON0.36 billion, down 0.3% compared to the third quarter of 2014.
In January-September 2015, the total value of the pharmaceutical market stood at RON8.84 billion, down 1.2% from the corresponding period a year earlier. In lei, sales of prescription drugs (Rx) fell 6.7% in pharmacies, OTC sales grew 18.1% and hospital sales grew 7.1%.
In the past 12 months, Romania’s pharmaceutical market stood at RON12.18 billion, up 2.1% compared to the previous 12 months (October 2013-September 2014). In lei, sales of prescription drugs (Rx) fell 2.7% in pharmacies, OTC sales grew 18.4% and hospital sales grew 8.8%.
Sanofi (including Zentiva) remained the top player with RON853.8 million, followed by Hoffmann La Roche with sales of RON698.5 million and Novartis (including Sandoz) with RON679.5 million.
The top ten is completed by Servier (including Egis) with RON644.3 million, Pfizer (RON568.2 million), Sun Pharma (including Terapia) with RON531.7 million, GlaxoSmithKline (RON514.1 million), AstraZeneca (RON475.5 million), Merck & Co (RON375 million) and Krka (RON355.1 million).